Abstract
Policy Points A total of 21 states have passed drug price transparency laws with the goals of creating accountability around drug pricing and facilitating the development of policy solutions to address high prices. These laws vary in design but often require manufacturers to report the wholesale acquisition cost of drugs above a certain threshold for new drugs or of drugs that undergo a price increase above a certain margin, along with other data such as the manufacturer's costs. Initial findings suggest these laws may have contributed toward informing policymaking based on newly available public information but do not appear to have affected drug prices.